Cytokinetics Data Shows Aficamten Outperforms Metoprolol in HCM Treatment
Event summary
- Cytokinetics presented new data at ESC Heart Failure 2026 showing aficamten (MYQORZO) outperformed metoprolol in treating obstructive hypertrophic cardiomyopathy (oHCM).
- Long-term data from FOREST-HCM showed no increase in arrhythmias with aficamten treatment up to 96 weeks.
- Real-world evidence highlighted significant activity impairment in oHCM patients, with 26.6% average impairment due to the disease.
- Aficamten demonstrated improvements in left atrial mechanics, suggesting beneficial effects on atrial mechanics in oHCM patients.
The big picture
Cytokinetics' data reinforces aficamten's position as a leading therapy for oHCM, addressing a significant unmet need in cardiovascular care. The findings come at a time when the HCM market is expanding, with increasing recognition of the disease's prevalence and the need for targeted treatments. The company's ability to differentiate aficamten through robust clinical and real-world evidence will be critical in sustaining its growth trajectory.
What we're watching
- Clinical Superiority
- Whether aficamten's demonstrated superiority over metoprolol will accelerate its adoption in the oHCM treatment landscape.
- Regulatory Pathway
- The pace at which Cytokinetics can expand aficamten's approvals into additional indications, such as pediatric oHCM.
- Market Penetration
- How Cytokinetics will leverage this data to increase market share against existing therapies for HCM.